Takeda partner Finch joins forces with Crestovo, leaping into a mid-stage microbiome study
About 6 months after Takeda partnered up with microbiome biotech Finch Therapeutics on a preclinical program for IBD, the Somerville, MA-based company has struck a deal to merge with Crestovo and pivot to a mid-stage therapy.
Back at the end of June, Cambridge, MA-based Crestovo launched a Phase II trial dubbed PRISM 3 for CP101, a microbiome program for Clostridium difficile infection, which Finch has also been targeting.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
